Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary
- Conditions
- Rhinitis
- First Posted Date
- 2013-10-29
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 300
- Registration Number
- NCT01971086
- Locations
- 🇭🇺
40.56.36002 Boehringer Ingelheim Investigational Site, Budapest, Hungary
🇭🇺40.56.36003 Boehringer Ingelheim Investigational Site, Budapest, Hungary
🇭🇺40.56.36001 Boehringer Ingelheim Investigational Site, Budapest, Hungary
Ventilator Adapters for Combivent Respimat
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11
- Registration Number
- NCT01969539
- Locations
- 🇺🇸
1012.65.00001 Boehringer Ingelheim Investigational Site, Danbury, Connecticut, United States
🇺🇸1012.65.00002 Boehringer Ingelheim Investigational Site, Fort Worth, Texas, United States
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 229
- Registration Number
- NCT01969721
- Locations
- 🇨🇿
1237.11.42004 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇩🇪1237.11.49003 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany
🇩🇪1237.11.49005 Boehringer Ingelheim Investigational Site, Hamburg, Germany
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 75
- Registration Number
- NCT01969747
- Locations
- 🇦🇹
1245.78.43001 Boehringer Ingelheim Investigational Site, Graz, Austria
🇩🇪1245.78.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.
- Conditions
- Healthy
- Interventions
- Drug: BI 207127Drug: Moxifloxacin (Avalox®)Drug: BI 207127 placeboDrug: Faldaprevir placeboDrug: Faldaprevir
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01965431
- Locations
- 🇩🇪
1241.40.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 813
- Registration Number
- NCT01964352
- Locations
- 🇺🇸
1237.25.10508 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇧🇪1237.25.32002 Boehringer Ingelheim Investigational Site, Turnhout, Belgium
🇧🇪1237.25.32004 Boehringer Ingelheim Investigational Site, Brussels, Belgium
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion
- Conditions
- Catheter ObstructionVascular Access Devices
- Interventions
- Drug: ActilyseDrug: Saline solution
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01958164
- Locations
- 🇷🇺
135.323.3 Boehringer Ingelheim Investigational Site, Krasnoyarsk, Russian Federation
🇷🇺135.323.1 Boehringer Ingelheim Investigational Site, Akhangelsk, Russian Federation
🇷🇺135.323.2 Boehringer Ingelheim Investigational Site, Krasnodar, Russian Federation
Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4
- Registration Number
- NCT01957657
- Locations
- 🇩🇪
1241.32.1 Boehringer Ingelheim Investigational Site, Kiel, Germany
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BI 1034020Drug: Placebo to BI 1034020
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 35
- Registration Number
- NCT01958060
- Locations
- 🇩🇪
1312.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
🇩🇪1312.1.2 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
- Conditions
- Leukemia, Myelomonocytic, ChronicMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01957644
- Locations
- 🇫🇷
1230.33.33002 Boehringer Ingelheim Investigational Site, Marseille, France
🇫🇷1230.33.33001 Boehringer Ingelheim Investigational Site, Paris, France
🇩🇪1230.33.49002 Boehringer Ingelheim Investigational Site, Dresden, Germany